Natco Pharma’s Finished Dosage Formulations manufacturing facility at Parawada in Visakhapatnam has received four observations from the US Food and Drug Administration. The regulatory inspection was conducted at the facility between August 17 and August 21, 2026. Following the inspection, the US FDA issued a Form 483 containing four observations. A Form 483 records inspectional observations identified by FDA investigators and does not by itself represent a final determination of regulatory compliance. Natco Pharma has described the observations as procedural in nature. The company has expressed confidence in addressing the observations comprehensively within the required timeframe. It is expected to submit its response and corrective action details within 15 days. The Visakhapatnam facility is involved in manufacturing finished dosage formulations for pharmaceutical products. The development is being closely watched by investors because of the facility’s role in the company’s operations and regulatory compliance. Natco Pharma shares closed at ₹883.80 on the BSE on Friday, August 21, gaining 0.69% during the session. The company is also dealing with weaker quarterly financial performance and has announced plans to raise up to ₹2,000 crore. Further updates on the company’s response to the FDA observations will be important for investors and stakeholders.